Total Liabilities Summary of Newbury Pharmaceuticals AB (publ)

Newbury Pharmaceuticals AB (publ)'s latest annual total liabilities in 2024 was 38.95 Million SEK , up 65.49% from previous year.
Newbury Pharmaceuticals AB (publ)'s latest quarterly total liabilities in 2024 Q4 was 38.95 Million SEK , down -4.28% from previous quarter.
Newbury Pharmaceuticals AB (publ) reported annual total liabilities of 23.53 Million SEK in 2023, up 29.79% from previous year.
Newbury Pharmaceuticals AB (publ) reported annual total liabilities of 18.13 Million SEK in 2022, up 317.95% from previous year.
Newbury Pharmaceuticals AB (publ) reported quarterly total liabilities of 40.69 Million SEK for 2024 Q3, down -6.12% from previous quarter.
Newbury Pharmaceuticals AB (publ) reported quarterly total liabilities of 43.34 Million SEK for 2024 Q2, down -10.5% from previous quarter.

Annual Total Liabilities Chart of Newbury Pharmaceuticals AB (publ) (2024 - 2021)

Name	Total Liabilities	Total Liabilities Difference
AcuCort AB	10.97 Million SEK	-254.934%
AlzeCure Pharma AB (publ)	8.22 Million SEK	-373.49%
BioGaia AB (publ)	302.84 Million SEK	87.137%
Enzymatica AB (publ)	49.3 Million SEK	20.989%
Enorama Pharma AB (publ)	14.84 Million SEK	-162.37%
Gabather AB (publ)	6.87 Million SEK	-466.356%
Klaria Pharma Holding AB (publ.)	31.98 Million SEK	-21.785%
Moberg Pharma AB (publ)	24 Million SEK	-62.261%
Nanexa AB (publ)	36.42 Million SEK	-6.937%
ODI Pharma AB	10.05 Million SEK	-287.306%
Orexo AB (publ)	727.7 Million SEK	94.647%
Probi AB (publ)	181.31 Million SEK	78.516%
Swedencare AB (publ)	2.31 Billion SEK	98.318%
Swedish Orphan Biovitrum AB (publ)	40.16 Billion SEK	99.903%
Toleranzia AB	6.9 Million SEK	-463.815%
Vivesto AB	30.45 Million SEK	-27.919%